Glyco Discoveries, Inc.

Raleigh, NC Part of Glycan Therapeutics Corporation

UEI
PFBMHRWCG2G1
CAGE
9VWC3
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
  • Biotechnology Research Parent Glycan Therapeutics Corporation · Raleigh, NC KYG3DZSMH4R7
    • Glyco Discoveries, Inc.
SAM.gov registration date
Physical address
617 Hutton St, Raleigh, NC 27606, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation R42CA285005 National Cancer Institute (NIH) $1,551,338
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation R41CA285005 National Cancer Institute (NIH) $1,364,710

Quick answers

Is Glyco Discoveries, Inc. registered in SAM.gov?

Yes. Glyco Discoveries, Inc.'s SAM.gov registration is active through October 2, 2027.

What is Glyco Discoveries, Inc.'s most recent federal award?

Glyco Discoveries, Inc.'s most recent federal grant award is Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation (R42CA285005), from National Cancer Institute (NIH), on July 1, 2023.

On GovTribe

See Glyco Discoveries, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login